FindTrial
Sign In

The effect of anticoagulation therapy after splenectomy and hilum shunt for portal vein spongiform degeneration: A single-center, placebo-controlled, prospective clinical study

The effect of anticoagulation therapy after splenectomy and hilum shunt for portal vein spongiform degeneration: A single-center, placebo-controlled, prospective clinical study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022940
Enrollment
Unknown
Registered
2019-05-04
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cavernous transformation of portal vein

Interventions

Experimental group:Anticoagulation treatment
control group:No

Sponsors

Children's Hospital of Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1) confirmed cavernous degeneration of portal vein; 2) splenectomy + hilum shunt has been performed.

Exclusion criteria

Exclusion criteria: 1) abdominal malignant tumor, potential primary blood disease, burga syndrome, inferior vena cava membranous obstruction, liver cirrhosis or existing extrahepatic thrombosis; 2) participating in other treatment trials or failing to regularly assess liver function; 3) complicated with immune diseases; 4) prepare for liver transplantation.

Design outcomes

Primary

MeasureTime frame
Portal thrombosis;—

Secondary

MeasureTime frame
Liver function;Bleeding or clotting;—

Countries

China

Contacts

Public ContactChunbao Guo

Children's Hospital of Chongqing Medical University

guochunbao@foxmail.com+86 13032386618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026